Moksha8 takes in $39M to commercialize drugs for Asia
See our story about this San Francisco drug developer — at least, what is potentially a San Francisco company — in today’s daily briefing at VentureBeat Life Sciences.
Next Story: Analysis: Problems and possibilities in MySpace’s new developer platform
Previous Story: H-P’s “great-grandchild” gets $7.7M for portable diagnosis
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.